Latest News

Timely, factual reporting across artificial intelligence, cybersecurity, companies and markets, EU AI regulation, health and biotech, and climate and energy.

  1. The PASCAL indication covers eligible patients with severe, symptomatic tricuspid regurgitation despite optimal medical treatment.

  2. The preliminary prospectus sets no share count or price range; sales cannot begin until the registration statement takes effect.

  3. The proposed mix of Vietnamese offshore wind, Malaysian solar and battery storage is intended to supply up to 1.3 GW to Singapore.

  4. OpenAI’s dataset covers work-related messages from individual ChatGPT plans across nearly 100 countries, excluding enterprise use and Codex.

  5. The flaw affects Brotli data processed by Node.js’s zlib module, with crashes, memory disclosure or code execution possible for attacker-supplied input.

  6. The phase 3 trial enrolled 455 patients in China with advanced nonsquamous lung cancer and PD-L1 scores below 1%.

  7. The global Phase III trial enrolled 594 patients with previously treated, CLDN18.2-positive gastric or related cancers.

  8. The proposed Kimberley campus would use a private microgrid, with up to 5,200MW of solar and 1,500MW of wind capacity.

  9. Genmab will conduct the proposed trial, and Incyte plans to share its funding and provide INCB161734.

  10. The phase 2a study enrolled 31 patients who could not receive or declined cisplatin-based chemotherapy.